Skip to main content

Advertisement

SpringerLink
Log in

Therapeutic options in nonalcoholic fatty liver disease

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Nonalcoholic fatty liver disease, an entity that includes nonalcoholic steatohepatitis, is typically a benign, indolent condition. However, in a subset of patients, the clinical course may progress to advanced cirrhosis, end-stage liver disease, or hepatocellular carcinoma. Unfortunately, the pathogenesis, natural history, and potential therapies for these disorders remain poorly understood. Identifying patients who should be targeted for potential treatment remains difficult. Liver biopsy should be considered to assess the degree of hepatic inflammation and fibrosis, because physical examination findings, biochemical parameters, and the results of radiographic studies have been shown to correlate poorly with the severity of steatohepatitis and fibrosis. Although there is some evidence suggesting that obesity, diabetes mellitus, older age, and perhaps an aspartate transaminase:alanine aminotransaminase ratio higher than 1 may be predictors of more advanced fibrosis, histology remains the gold standard. Most patients with simple hepatic steatosis appear to follow a benign course and probably do not require aggressive therapy. Conversely, patients with steatohepatitis with extensive inflammation and fibrosis are the patients who are most likely to benefit from effective therapies. The most commonly recommended treatment is weight loss. Existing data suggest that rapid weight loss may promote hepatic inflammation and fibrosis; therefore, gradual weight loss should be recommended. Large, randomized, controlled trials evaluating the long-term histologic impact and clinical outcomes of weight loss strategies are lacking. Potentially promising pharmacologic therapies include insulin-sensitizing oral hypoglycemic agents such as metformin and the thiazolidenediols, antihyperlipidemic agents such as gemfibrozil or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, vitamin E and other antioxidants, ursodeoxycholic acid, and betaine. As with weight loss, data regarding the efficacy of these pharmacologic options are limited. In addition, there are no widely accepted guidelines to help direct the clinician in the optimal use of these agents in patients with nonalcoholic fatty liver diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Ludwig J, Viggiano TR, McGill DB, et al.: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980, 55:434–438.

    PubMed  CAS  Google Scholar 

  2. Reid AE: Nonalcoholic steatohepatitis. Gastroenterology 2001, 121:710–723. An excellent recent review of NAFLD/NASH, containing up-to-date information about the epidemiology, pathophysiology, and clinical manifestations of NASH.

    Article  PubMed  CAS  Google Scholar 

  3. Angulo P: Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221–1231.

    Article  PubMed  CAS  Google Scholar 

  4. Caldwell SH, Li TH, Anderson SM: Nonalcoholic steatohepatitis (NASH). In Schiff’s Diseases of the Liver, edn 9. Edited by Schiff ER, Sorrell M, Maddrey WC. Philadelphia: Lippincott Williams & Wilkins, In press.

  5. Rozental P, Biava C, Spencer H, et al.: Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967, 12:198–208.

    Article  PubMed  CAS  Google Scholar 

  6. Drenick EJ, Simmons F, Murphy JF: Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass. N Engl J Med 1970, 282:829–834.

    Article  PubMed  CAS  Google Scholar 

  7. Keeffe EB, Adesman PW, Stenzel P, et al.: Steatosis and cirrhosis in an obese diabetic: resolution of fatty liver by fasting. Dig Dis Sci 1987, 32:441–445.

    Article  PubMed  CAS  Google Scholar 

  8. Eriksson S, Eriksson KF, Bondesson L: Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986, 220:83–88.

    Article  PubMed  CAS  Google Scholar 

  9. Palmer M, Schaffner F: Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990, 99:1408–1413.

    PubMed  CAS  Google Scholar 

  10. Ueno T, Sugawara H, Sujaku K, et al.: Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27:103–107.

    Article  PubMed  CAS  Google Scholar 

  11. Andersen T, Gluud C, Franzmann MB, et al.: Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12:224–229.

    Article  PubMed  CAS  Google Scholar 

  12. Okita M, Hayashi M, Sasagawa T, et al.: Effect of a moderately energy-restricted diet on obese patients with fatty liver. Nutrition 2001, 17:542–547. The results of this study suggest that in addition to a low-calorie diet, increased consumption of specific dietary constituents (such as omega-3 polyunsaturated fatty acids, vitamin A, and vegetables) may be beneficial in patients with NAFLD/NASH.

    Article  PubMed  CAS  Google Scholar 

  13. Vajro P, Fontanella A, Perna C, et al.: Persistent hyperaminotransferasemia resolving after weight reduction in obese children. J Pediatr 1994, 125:239–241.

    Article  PubMed  CAS  Google Scholar 

  14. Hasegawa T, Yoneda M, Nakamura K, et al.: Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001, 15:1667–1672. The more recent of two human studies reporting the potential benefit vitamin E in patients with NAFLD/NASH. This is the only vitamin E study providing hepatic histology as a therapeutic endpoint.

    Article  PubMed  CAS  Google Scholar 

  15. Caldwell SH, Hespenheide EE, Redick JA, et al.: A pilot study of a thiazolidinedione, troglitazone in nonalcoholic steatohepatitis. Am J Gastroenterol 2001, 96:519–525.

    Article  PubMed  CAS  Google Scholar 

  16. Duchini A, Brunson ME: Roux-en-Y gastric bypass for recurrent nonalcoholic steatohepatitis in liver transplant recipients with morbid obesity. Transplantation 2001, 72:156–159.

    Article  PubMed  CAS  Google Scholar 

  17. Hocking MP, Davis GL, Franzini DA, et al.: Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci 1998, 43:2493–2499.

    Article  PubMed  CAS  Google Scholar 

  18. Silverman EM, Sapala JA, Appelman HD: Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol 1995, 104:23–31.

    PubMed  CAS  Google Scholar 

  19. Enat R, Nagler A, Bassan L, et al.: Night blindness and liver cirrhosis as late complications of jejunoileal bypass surgery for morbid obesity. Isr J Med Sci 1984, 20:543–546.

    PubMed  CAS  Google Scholar 

  20. Griffen WO Jr, Young VL, Stevenson CC: A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977, 186:500–509.

    Article  PubMed  Google Scholar 

  21. Rucker RD Jr, Horstmann J, Schneider PD, et al.: Comparisons between jejunoileal and gastric bypass operations for morbid obesity. Surgery 1982, 92:241–249.

    PubMed  Google Scholar 

  22. Cairns SR, Kark AE, Peters TJ: Raised hepatic free fatty acids in a patient with acute fatty liver after gastric surgery for morbid obesity. J Clin Pathol 1986, 39:647–649.

    PubMed  CAS  Google Scholar 

  23. Allam C, Bala’a M, Shamma’a M: Evolution of liver disease in morbid obesity after small-intestinal bypass and its restoration: a case report. Arch Pathol Lab Med 1983, 107:195–198.

    PubMed  CAS  Google Scholar 

  24. Hamilton DL, Vest TK, Brown BS, et al.: Liver injury with alcoholiclike hyalin after gastroplasty for morbid obesity. Gastroenterology 1983, 85:722–726.

    PubMed  CAS  Google Scholar 

  25. Assy N, Israel F, Svalb S, et al.: Orlistat (Xenical) reverses fatty liver disease and improves hepatic fibrosis in obese patients with nash [abstract]. Hepatology 2001, 34:251A. This is the only published trial evaluating the impact of pharmacologically assisted weight loss in patients with NAFLD.

    Google Scholar 

  26. Lin HZ, Yang SQ, Chuckaree C, et al.: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000, 6:998–1003.

    Article  PubMed  CAS  Google Scholar 

  27. Coyle WJ, Delaney N, Yoshihashi A, et al.: Metformin treatment in patients with nonalcoholic steatohepatitis normalizes LFTS and improves histology [abstract]. Gastroenterology 1999, 116:A1198. Although this is the earliest of three human studies that suggest that metformin may be beneficial in patients with NASH, this is the only published report of a completed study that provides hepatic histology following therapy.

    Google Scholar 

  28. Nair S, Diehl AM, Perrillo R: Metformin in nonalcoholic steatohepatitis (NASH): efficacy and safety: a preliminary report [abstract]. Gastroenterology 2002, 122(Suppl 1).

  29. Marchesini G, Brizi M, Bianchi G, et al.: Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358:893–894.

    Article  PubMed  CAS  Google Scholar 

  30. Katoh S, Hata S, Matsushima M, et al.: Troglitazone prevents the rise in visceral adiposity and improves fatty liver associated with sulfonylurea therapy—a randomized controlled trial. Metabolism 2001, 50:414–417.

    Article  PubMed  CAS  Google Scholar 

  31. Acosta RC, Molina EG, O’Brien CB, et al.: The use of pioglitazone in nonalcoholic steatohepatitis [abstract]. Gastroenterology 2001, 120(Suppl):A-546.

    Article  Google Scholar 

  32. Neuschwander-Tetri BA, Sponseller C, Hampton KK, et al.: Rosiglitazone improves insulin sensitivity, ALT, and hepatic steatosis in patients with nonalcoholic steatohepatitis [abstract]. Gastroenterology 2002, 122(Suppl 1):4.

    Google Scholar 

  33. Laurin J, Lindor KD, Crippin JS, et al.: Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholinduced steatohepatitis: a pilot study. Hepatology 1996, 23:1464–1467.

    Article  PubMed  CAS  Google Scholar 

  34. Basaranoglu M, Acbay O, Sonsuz A: A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis [letter; comment]. J Hepatol 1999, 31:384.

    Article  PubMed  CAS  Google Scholar 

  35. Horlander JC, Kwo PY, Cummings O, et al.: Atorvastatin for the treatment of NASH [abstract]. Gastroenterology 2001, 120(Suppl):A-544.

    Google Scholar 

  36. Poli G, Albano E, Biasi F, et al.: Lipid peroxidation stimulated by carbon tetrachloride or iron and hepatocyte death: protective effect of vitamin E. In Free Radicals in Liver Injury. Edited by Poli G, Cheeseman KH, Diazani MU, Slater TF. Oxford: IRL Press Ltd; 1985:207–215.

    Google Scholar 

  37. Parola M, Muraca R, Dianzani I, et al.: Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992, 308:267–270.

    Article  PubMed  CAS  Google Scholar 

  38. Parola M, Leonarduzzi G, Biasi F, et al.: Vitamin E dietary supplementation protects against carbon tetrachloride-induced chronic liver damage and cirrhosis. Hepatology 1992, 16:1014–1021.

    Article  PubMed  CAS  Google Scholar 

  39. Lavine JE: Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000, 136:734–738.

    Article  PubMed  CAS  Google Scholar 

  40. Malekzadeh R, Merat S, Sotoudeh M, et al.: Probucol in the treatment of non-alcoholic steatohepatitis: a placebo-controlled double-blind study [abstract]. Gastroenterology 2002, 122(Suppl 1):A-24.

    Google Scholar 

  41. Gulbahar O, Karasu ZA, Ersoz G, et al.: Treatment of non-alcoholic steatohepatitis with N-acetylcysteine [abstract]. Gastroenterology 2000, 118:A1444.

    Article  Google Scholar 

  42. Vajro P, Franzese A, Valerio G, et al.: Lack of efficacy of ursodeoxycholic acid for the treatment of liver abnormalities in obese children. J Pediatr 2000, 136:739–743.

    Article  PubMed  CAS  Google Scholar 

  43. Guma C, Viola L, Thome M, et al.: Ursodeoxycholic acid in the treatment of non-alcoholic steatohepatitis: results of a prospective clinical controlled trial [abstract]. Hepatology 1997, 26:387A.

    Article  Google Scholar 

  44. Ceriani R, Brunati S, Morini L, et al.: Effect of Ursodeoxycholic acid plus diet in patients with non-alcoholic steatohepatitis [abstract]. Hepatology 1998, 28:386A.

    Google Scholar 

  45. Abdelmalek MF, Angulo P, Jorgensen RA, et al.: Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001, 96:2711–2717.

    Article  PubMed  CAS  Google Scholar 

  46. Fu C, Esrason K, Alshak N, et al.: Dietary lecithin, antioxidant and vitamin b complex (LAB) decrease hepatic steatosis on patients with nonalcoholic steatohepatitis (NASH) [abstract]. Gastroenterology 1998, 114:A1243.

    Article  Google Scholar 

  47. Li Z, Yang SQ, Lin HZ, et al.: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease [abstract]. Gastroenterology 2002, 122(Suppl 1):4.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Health Center of Excellence, University of Virginia Health System, Lee Street, 22908, Charlottesville, VA, USA

    Jeffrey L. Tokar MD & Carl L. Berg MD

Authors
  1. Jeffrey L. Tokar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carl L. Berg MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tokar, J.L., Berg, C.L. Therapeutic options in nonalcoholic fatty liver disease. Curr Treat Options Gastro 5, 425–436 (2002). https://doi.org/10.1007/s11938-002-0030-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-002-0030-1

Keywords

Search

Navigation